Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer

X Zhang,Y S Ma,X D Tian,Y M Yang
DOI: https://doi.org/10.3760/cma.j.cn112139-20230510-00199
2023-01-01
Abstract:Pancreatic cancer is a highly malignant tumor. About 75% of patients with pancreatic cancer who underwent radical surgical resection will still experience postoperative recurrence. Neoadjuvant therapy could improve outcomes in patients with borderline resectable pancreatic cancer,has become a consensus;however it is still controversial in resectable pancreatic cancer. Limited high-quality randomized controlled trial studies support the routine initiation of neoadjuvant therapy in resectable pancreatic cancer. With the development of new technologies, such as next-generation sequencing, liquid biopsy, imaging omics, and organoids, patients are expected to benefit from the precision screening of potential candidates for neoadjuvant therapy and individualized treatment strategy.
What problem does this paper attempt to address?